In 305 adults with ALS, the oral RIPK1 inhibitor SAR443820 did not slow functional decline versus placebo at 24 weeks (ALSFRS-R change −6.73 vs −6.32; difference −0.41, non-significant) and caused more discontinuations, mainly raised liver enzymes.
RCTn = 305
Cudkowicz et al. Safety, tolerability, and efficacy of RIPK1 inhibitor, SAR443820, in amyotrophic lateral sclerosis (HIMALAYA): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial